CHRNA7 and schizophrenia: The adverse effects of the inhibition of microglial activation on cognitive impairment might be diminished by the targeting of microglia-expressed receptors (e.g., GLP-1R and α7nAChR agonists), although few studies on this topic have been conducted with patients with schizophrenia or animal models of the disease.